

## Publications 2016

Desra A., Breen J, Harper S, Slavin MA, Worth LJ.

Aseptic technique for accessing central venous catheters: applying a standardised tool to audit 'scrub the hub' practices.

J Vasc Access, 2016, Feb 8.

Douglas AP, Chen SCA, Slavin MA.

Emerging infections caused by non-Aspergillus filamentous fungi. Invited review.

Clin Microbiol Infect 2016 Jan 23.

Haeusler GM, Carlesse F, Phillips RS.

An updated systematic review and meta-analysis of the predictive value of serum biomarkers in the assessment of fever during neutropenia in children with cancer.

Pediatr Infect Dis J. 2013 Oct;32(10):e390-6

Haeusler GM, Levene I.

What are the risk factors for antibiotic resistant Gram-negative bacteraemia in children with cancer?

Arch Dis Child. 2015 Sep;100(9):895-8.

Haeusler GM, Mechinaud F, Daley AJ, Starr M, Shann F, Connell TG, Bryant PA et al.

Antibiotic-resistant Gram-negative bacteremia in pediatric oncology patients--risk factors and outcomes.

Pediatr Infect Dis J. 2013 Jul;32(7):723-6.

Haeusler GM, Phillips RS, Lehrnbecher T, Sung L, Ammann RA.

The reporting of outcomes in studies of fever and neutropenia in children with cancer: time for consensus.

Pediatr Blood Cancer. 2013 Oct;60(10):1563-4.

Haeusler GM, Sung L, Ammann RA, Phillips B.

Management of fever and neutropenia in paediatric cancer patients: room for improvement?

Curr Opin Infect Dis. 2015 Dec;28(6):532-8.

Hiong A, Thursky KA, Teh BW, Haeusler GM, Slavin MA, Worth LJ.

Sepsis following cancer surgery: the need for early recognition and standardised clinical care.

Expert Rev Anti Infect Ther 2016 Apr;14(4):425-33.

Kennedy K, Daveson K, Slavin M, vanHal S, Sorrell T, Lee A, Marriott D, Chapman, B et al.

Mucormycosis in Australia: contemporary epidemiology and outcomes.

Clinical Microbiol Infect, 2016 January 19.

Phillips RS, Sung L, Amman RA, Riley RD, Castagnola E, Haeusler GM, Klaassen R et al.

Predicting microbiologically defined infection in febrile neutropenic episodes in children: global individual participant data multivariable meta-analysis.

Br J Cancer. 2016 Mar 15;114(6):623-30.

Slavin MA, Thursky KA.

Isavuconazole: A role for the newest broad-spectrum triazole. Invited commentary. Lancet, accepted December 2015

Teh BW, Worth LJ, Harrison SJ, Slavin MA.

Antiviral prophylaxis for varicella zoster virus infections in patients with myeloma in the era of novel therapies.

Leuk Lymphoma, Leuk Lymphoma. 2016 Jan 4:1-4.

Teng JC, Lingaratnam SM, Trubiano JA, Thursky KA, Slavin MA, Worth LJ.

Oral pristinamycin for treatment of resistant gram-positive infections in patients with cancer: evaluation of clinical outcomes. International Journal of Antimicrobial Agents Accepted Jan 21st

Trubiano JA, Chen C, Cheng AC, Grayson ML, Slavin MA, Thursky KA

National Antimicrobial Prescribing Survey (NAPS). Antimicrobial allergy 'labels' drive inappropriate antimicrobial prescribing: lessons for stewardship.

J Antimicrob Chemother. 2016 Feb 18. pii: dkw008. [Epub ahead of print]

## **Publications 2015**

Barnes R, Earnshaw S, Herbrecht R, Morrissey O, Slavin M, Bow E, McDade C et al.

Economic comparison of an empirical versus diagnostic-driven strategy for treating invasive fungal disease in immunocompromised patients.

Clin Ther. 2015 Apr 16. pii: S0149-2918(15)00163-0.

Bow EJ, Vanness DJ, Slavin M, Cordonnier C, Cornely OA, Marks DI, Pagliuca A et al.

Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients.

BMC Infect Dis. 2015 Mar 17;15:128.

Doan T, Kirkpatrick C, Walker P, Slavin M, Ananda-Rajah M, Morrissey O, et al.

Primary antifungal prophylaxis in adult patients with acute lymphoblastic leukaemia: a multi-centre audit.

J Antimicrob Chemother, accepted Sept 2015.

Haeusler GM, Phillips RS, Lehrnbecher T, Thursky KA, Sung L, Ammann RA.

Core outcomes and definitions for pediatric fever and neutropenia research: a consensus statement from an international panel.

Pediatr Blood Cancer. 2015 Mar;62(3):483-9.

Herbrecht R, Patterson TF, Slavin MA, Marchetti O, Maertens J, Johnson EM et al.

Application of the 2008 Definitions for Invasive Fungal Diseases to the Trial Comparing Voriconazole versus Amphotericin B for Therapy of Invasive Aspergillosis. A Collaborative Study of the Mycoses Study Group (MSG 05) and the EORTC Infectious Diseases Group.

Clin Infect Dis, 2014 Nov 19. pii: ciu911. [Epub ahead of print]

Kidd SE, Goeman E, Meis JF, Slavin MA, Verweij PE.

Multi-Triazole Resistant Aspergillus fumigatus infections in Australia.

Mycoses. 2015 Jun;58(6):350-5.

Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, J. et al.  
Combination Antifungal Therapy for Invasive Aspergillosis: Results of a Prospective,  
Comparative, Randomized, Double-Blind Clinical Trial.  
Ann Intern Med. 2015 Jan 20;162(2):81-89.

Martinez D, Ananda-Rajah MR, Suominen H, Slavin MA, Thursky KA, Cavedon L.  
Automatic detection of patients with invasive fungal disease from free-text computed  
tomography (CT) scans.  
J Biomed Inform. 2014 Nov 24. pii: S1532-0464(14)00239-1. doi: 10.1016/j.jbi.2014.11.009.  
[Epub ahead of print]

Slavin MA, Chen SCA.  
Clinical and Translational Mycology on the southern shores – perspective from the Australia  
and New Zealand Mycoses Interest Group.  
Microbiology Australia, accepted March 2015.

Slavin MA, Thursky KA.  
Improving the outcome of bloodstream infection in patients with haematological  
malignancies: looking beyond antibiotics.  
Leuk Lymphoma. 2015 Jun 19:1-9.

Slavin M, van Hal S, Sorrell T, Lee A, Marriott D, Daveson K, Kennedy K, Hajkowicz K et al.  
Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and  
determinants of mortality.  
Clin Microbiol Infect. 2015 May;21(5):490.e1-490.e10.

Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA.  
Risks, severity and timing of infections in patients with multiple myeloma: A longitudinal  
cohort study in the era of immunomodulatory drug therapy.  
Br J Haematol, 2015 Jun 24. doi: 10.1111/bjh.13532

Teh BW, Slavin MA, Thursky KA, Harrison SJ, Worth LJ.  
Prevention of viral infections in patients with multiple myeloma: The role of anti-viral  
prophylaxis and immunization.  
Expert Rev Anti-infective therapy, accepted August 2015

Teh BW, Worth LJ; Harrison SJ; Thursky KA, Slavin MA.  
Risks and burden of viral respiratory tract infections in patients with multiple myeloma in  
the era of immunomodulatory drugs and bortezomib: experience at an Australian Cancer  
Hospital.  
Support Care Cancer. 2015 Jul;23(7):1901-6.

Teng JC, Slavin MA, Teh BW, Lingaratnam SM, Ananda-Rajah MR, Worth LJ, et al.  
Epidemiology of Invasive Fungal Disease in Lymphoproliferative Disorders.  
Haematologica, 2015 Jul 23. pii: haematol.2015.126698. [Epub ahead of print].

Thursky KA, Worth LJ.  
Can mortality of cancer patients with fever and neutropenia be improved?  
Curr Opin Infect Dis. 2015 Dec;28(6):505-13.

Trubiano JA, Chen SC-A, Slavin MA.  
An approach to a pulmonary infiltrate in solid organ transplant recipients.  
Fungal Infection Reports.

Trubiano J, Crowe A, Worth L, Thursky K, Slavin M.  
Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort.  
J Antimicrob Chemother, 2015 Apr;70(4):1161-5.

Trubiano JA, Leung VK, Worth LJ, Teh BW, Thursky KA, Slavin MA.  
Candida glabrata fungaemia at an Australian cancer centre: epidemiology, risk factors and therapy.  
Leuk Lymphoma. 2015 Apr 24:1-9.

Trubiano JA, Leung VK, Chu MY, Worth LJ, Slavin MA, Thursky KA.  
The impact of antimicrobial allergy labels on antimicrobial usage in cancer patients.  
Antimicrob Resist Infect Control. 2015 Jun 1;4:23.

White PL, Wingard JR, Bretagne S, Löffler J, Patterson TF, Slavin MA, Barnes RA, et al.  
Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing.  
Clin Infect Dis. 2015 Jun 25. pii: civ507. [Epub ahead of print].

Wolf J, Tang L, Rubnitz JE, Brennan RC, Shook DR, Stokes DC, Monagle P, Curtis N et al.  
Monitoring Central Venous Catheter Resistance to Predict Imminent Occlusion: A Prospective Pilot Study.  
PLoS One. 2015 Aug 31;10(8):e0135904.

## **Publications 2014**

Ananda-Rajah MR, Martinez D, Slavin MA, Cavedon L, Dooley M, Cheng A, Thursky KA.  
Facilitating surveillance of invasive mould diseases in patients with haematological malignancies by screening computed tomography reports using natural language processing.  
PLoS One. 2014 Sep 24;9(9):e107797.

Blyth CC, Gilroy NM, Guy SD, Chambers ST, Cheong EY, Gottlieb T, McGuinness SL et al.  
Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation.  
Intern Med J. 2014 Dec;44(12b):1333-49.

Chang CC, Ananda-Rajah M, Belcastro A, McMullen B, Reid A, Dempsey K et al.  
Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works.  
Intern Med J. 2014 Dec;44(12b):1389-97.

Chau MM, Kong DC, van Hal SJ, Urbancic K, Trubiano JA, Cassumbhoy M, Wilkes J et al.  
Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy  
. Intern Med J. 2014 Dec;44(12b):1364-88.

Chen S, Sorrell TC, Chang CC, Paige EK, Bryant PA, Slavin MA.  
Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting.  
Intern Med J. 2014 Dec;44(12b):1315-32.

Cooley L, Dendle C, Wolf J, Teh BW, Chen SC, Boutlis C, Thursky KA.  
Consensus guidelines for diagnosis, prophylaxis and management of *Pneumocystis jirovecii* pneumonia in patients with haematological and solid malignancies.  
*Intern Med J.* 2014 Dec;44(12b):1350-63.

Fleming SA, Yannakou CK, Haeusler GM, Clark J, Grigg AP, Heath CH, Bajel A et al.  
Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation.  
*Intern Med J.* 2014 Dec;44(12b):1283-97.

Heng SC, Chen SC, Morrissey CO, Thursky K, Manser RL, De Silva HD, L. Halliday CL et al.  
Clinical utility of *Aspergillus* galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies.  
*Diagn Microbiol Infect Dis*, March 29, 2014.

Kuik KT, Trubiano J, Worth LJ, Harun NS, Steinfort D, Johnson D.  
*Pneumocystis jirovecii* pneumonia following everolimus treatment of metastatic breast cancer.  
*Med Mycol Case Rep.* 2014 Sep 16;6:34-6.

Lingarajnam SM, Slavin MA, Thursky KA, Teh BW, Haeusler GM, Seymour JF et al.  
*Pneumocystis jirovecii* pneumonia associated with gemcitabine chemotherapy: Experience at an Australian centre and guidelines for targeted prophylaxis.  
*Leuk Lymphoma*, 2014 Apr 9. [Epub ahead of print].

Macesic N, Fleming S, Kidd S, Madigan V, Chean R, Ritchie D, Slavin M.  
Protothecosis in hematopoietic stem cell transplantation: Case report and review of previous cases.  
*Transplant Infect Dis* 2014 May 5. doi: 10.1111/tid.12223. [Epub ahead of print]

Morrissey CO, Gilroy N, Macesic N, Walker P, Ananda-Rajah M, May Meryta et al.  
Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy.  
*Intern Med J.* 2014 Dec;44(12b):1298-314.

Neoh CF, Snell GI, Levvey B, Kotsimbos T, Morrissey CO, Slavin MA, Stewart K, Kong DC.  
Lung transplant recipients receiving voriconazole and skin squamous cell carcinoma risk in Australia. *Med J Aust.* 2014 Nov 3;201(9):543-4.

Peel T, Buising K, Thursky, Slavin M, Choong P.  
Infective Complications Following Tumour Endoprosthesis Surgery for Bone and Soft Tissue Tumours.  
*Eur J Surg Oncol.* 2014 Mar 4

Slavin MA, Thursky KA, Worth LJ, Chang CC, Morrissey CO, Blyth CC, Chen S, Szer J.  
Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting.  
*Intern Med J.* 2014 Dec;44(12b):1267-76.

Teh BW, Harrison S, Worth LJ, Thursky KA, Slavin MA.  
Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection.  
*Blood Rev.* 2014 Feb 10.

Teh BW, Teng JC, Urbancic K, Grigg A, Harrison SJ, Worth LJ, Slavin MA, Thursky KA.  
Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era  
of novel myeloma therapies.  
Haematologica, 2014 Oct 10.

Trubiano JA, George A, Barnett J, Siwan, M, Heriot A, Prince H M, Slavin M, Teh BW.  
A Different Kind of 'Allogenic Transplant: Successful Faecal Microbiota Transplantation for  
Recurrent and Refractory Clostridium difficile Infection in a Patient with Recurrent  
Aggressive B-cell Lymphoma.  
Leuk Lymphoma. 2014 May 14:1-8.

Trubiano JA, Paratz E, Wolf M, Teh B, Thursky KA, Slavin M.  
Disseminated Scedosporium prolificans infection in an 'extensive metabolizer': Navigating  
the minefield of drug interactions and pharmacogenomics."  
Mycoses. 2014 Apr 24. doi: 10.1111/myc.12199. [Epub ahead of print]

Trubiano JA, Slavin M, Teh B, Reed C, Worth L, Thursky KA.  
An unusual pain in the neck.  
Clin Infect Dis, 2014 Jun;58(11):1638-9.

van Hal SJ, Chen SC, Sorrell TC, Ellis DH, Slavin M, Marriott DM.  
Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre®  
YeastOne® for Candida albicans: a prospective observational cohort study.  
J Antimicrob Chemother, 2014 Apr 30. [Epub ahead of print]

Van Haal SJ, Gilroy N, Chen S, Thursky K, Worth LJ, Tam CS, Morrissey CO, Szer J, Slavin MA.  
A survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant  
haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New  
Zealand.  
Intern Med J. 2014 Dec;44(12b):1277-82.

Worth LJ. Vancomycin-resistant enterococci in patients with hematological malignancy:  
curbing an endemic pathogen.  
Leuk Lymphoma. 2014 Jun;55(6):1225-6.

Worth LJ, Slavin MA, Heath S, Szer J, Grigg AP.  
Ethanol versus heparin locks for the prevention of central venous catheter-associated  
bloodstream infections: a randomised trial in haematology patients with Hickman devices.  
Journal Hosp Infect, 2014 Sep;88(1):48-51.

## **Publications 2013**

Osthoff M, Chew E, Kelsey G, Panek-Hudson Y, Mason K, Szer J, Bajel A, Ritchie D, Slavin M.  
Disseminated toxoplasmosis after allogeneic stem cell transplantation in a seronegative  
recipient.  
Transplant Infectious Diseases. 2013 Feb;15(1):E14-9.

Neoh CF, Snell GI, Levvey B, Kotsimbos T, Morrissey CO, Slavin MA, Stewart K, Kong DCM.  
Voriconazole Pre-emptive Prophylaxis in Lung Transplant Patients.  
Transpl Infect Dis. 2013 Mar 25. doi: 10.1111/tid.12071. [Epub ahead of print]

Heng SC, Nation RL, Levvey B, Snell GI, Slavin MA, Kong DCM.  
Quantification of voriconazole in human bronchoalveolar lavage fluid and plasma using high-performance liquid chromatography with fluorescence detection .  
J Chromatography B, J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Jan 15;913-914:171-5.

Turner SJ, Chen SCA, Slavin MA, Kong DCM.  
Pharmacoeconomics of empirical antifungal use: What do we know?  
Expert Rev Pharmacoecon Outcomes Res. 2013 Apr;13(2):227-35.

Worth LJ, Kennon J, Patil S, Cheng AC.  
Challenges in performing surveillance for central line associated bacteraemia in haematology-oncology units.  
Intern Med J. 2013 Apr;43(4):466-7.

Neoh CF, Liew D, Slavin M, Marriott D, Chen S, Morrissey O, Stewart K, Kong DCM.  
Economic Evaluation of Micafungin versus Liposomal Amphotericin B (LAmB) for the Treatment of Candidaemia and Invasive Candidiasis (IC).  
Mycoses. 2013 Mar 18. doi: 10.1111/myc.12071.

Heng SC, Slavin MA, Al-Badriyeh D, Kirsas S, Thursky K, Nation RL, Seymour JF et al.  
Pharmacoeconomic evaluation of fluconazole versus posaconazole and voriconazole for antifungal prophylaxis in acute myeloid leukaemia patients undergoing consolidation chemotherapy.  
J Antimicrob Chemother. 2013 Jul;68(7):1669-78. doi: 10.1093/jac/dkt068.

Slavin MA, Thursky KA  
Outpatient therapy for fever and neutropenia is safe but implementation is the key.  
J Clin Oncol. 2013 Mar 20;31(9):1128-9.

Paterson DL;  
Steering Group of the Australasian Society for Infectious Diseases Clinical Research Network.  
Determining research priorities for Infectious Disease Clinical trials.  
Med J Aust. 2013 Mar 18;198(5):270-2.

Neoh CF, Liew D, Slavin MA, Marriott D, Chen SCA, Morrissey O, Stewart K, Kong DCM.  
Economic Evaluation of Micafungin versus Caspofungin for the Treatment of Candidaemia and Invasive Candidiasis.  
Intern Med J. 2013 Jun;43(6):668-77. doi: 10.1111/imj.12110.PMID:23461421[PubMed - in process]

Teh BW, Khot AS, Harrison SJ, Prince HM, Slavin MA.  
A messenger at the door: CMV retinitis in myeloma patients with progressive disease.  
Transpl Infect Dis. 2013 Jun 23. doi: 10.1111/tid.12106. [Epub ahead of print]PMID:23790037

CO Morrissey, SCA. Chen, TC. Sorrell, S Milliken, PG. Bardy, KF. Bradstock, et al. for the Australasian Leukaemia Lymphoma Group and the Australia and New Zealand Mycology Interest Group. Galactomannan- and PCR-directed versus the standard culture- and histological-based antifungal strategy for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial.  
Lancet Infect Dis. 2013 Jun;13(6):519-28.2013

Heng SC, Morrissey O, Chen SCA, Thursky K, Manser RL, Nation RL, Kong DCM, Slavin MA. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult haematology patients: a systematic review and meta-analysis.

Crit Rev Microbiol, 2013 Jun 25. [Epub ahead of print]

Haeusler GH, Slavin MA, Seymour JF, Lingaratnam S, The BW, Tam CS, Thursky KA, Worth LJ. Late-onset *Pneumocystis jirovecii* pneumonia following FCR chemotherapy: extended prophylaxis required for prevention.

Eur J Haematol. 2013;91(2):157-63.

Chen SC, Korman TM, Slavin MA, Marriott D, Byth K, Bak N, Currie BJ, Hajkovicz K et al. on behalf of the Australia and New Zealand Mycoses Interest Group (ANZMIG)-CryptococcusStudy. Antifungal therapy and management of complications of cryptococcosis due to *Cryptococcus gattii*.

Clin Infect Dis. 2013 May 22. [Epub ahead of print]

Lingaratnam S, Mellerick A, Worth LJ, Green M, Renwick W, Guy S, Filshie R, et al. Feasibility of early discharge strategies for neutropenic fever: outcomes of a Victorian organisational readiness assessment and pilot.

Intern Med J. 2013 Sep;43(9):979-86.

Heng SC, Snell G, Levvey B, Keating D, Westall G, Williams T, Whitford H, Nation R et al. Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients.

Antimicrob Agents Chemother. 2013 Sep;57(9):4581-3. doi: 10.1128/AAC.00942-13. Epub 2013 Jul 1.

Wolf J, Curtis N, Worth LJ, Flynn PM.

Central line-associated bloodstream infection in children: an update on treatment.

Pediatr Infect Dis J. 2013 Aug;32(8):905-10.

Neoh CF, Slavin M, Chen SCA, Stewart K, Kong DCM. Echinocandins in the Treatment of Candidaemia and Invasive Candidiasis (IC): Clinical and Economic Perspectives.

International Journal of Antimicrobial agents 2014: 43 (2014) 207–214

Leung VKY, Harper SE, Slavin MA, Thursky KA, Worth LJ.

Are they protected? Immunity to vaccine preventable diseases in healthcare workers at an Australian hospital.

Aust NZ Journal of Public Health; 2014 Feb;38(1):83-6.

Gardiner BJ, Slavin MA, Korman TM and Stuart RL.

Hampered by historical paradigms – echinocandins and the treatment of *Candida* endocarditis.

Mycoses, 2013 Nov 20. doi: 10.1111/myc.12154. [Epub ahead of print]

Teh BW, Azzato FA, Lingaratnam SM, Slavin MA, Worth LJ.

Molecular diagnosis of *Pneumocystis jirovecii* in patients with malignancy: Clinical significance of quantitative PCR.

Medical Mycology, 2014;Feb 28 [Epub ahead of print]



Teh BW, Slavin MA.  
More than a feeling: New approach required for assessing immunosuppression.  
Commentary. *Leuk Lymphoma*, 2014;55(5):975-6.

Trubiano JA, Worth LJ, Thursky KA, Slavin MA.  
The prevention and management of infections due to multi-drug-resistant organisms in haematology patients.  
*Br J Clin Pharmacol*. 2013 Dec 17. doi: 10.1111/bcp.12310. [Epub ahead of print]

## **Publications 2012**

Ananda-Rajah MR; Grigg AP, Downey MT, Bajel A, Spelman T; Cheng A; Thursky K, Vincent J, Slavin M. Effectiveness and safety of fluconazole, itraconazole, voriconazole and posaconazole prophylaxis over a 12-year period in patients with acute myeloid leukaemia /myelodysplastic syndrome undergoing cytotoxic chemotherapy.  
*Haematologica*. 2012 Mar;97(3):459-63.

Ananda-Rajah MR, Grigg A, Slavin MA. Making sense of posaconazole therapeutic drug monitoring: a practical approach.  
*Curr Opin Infect Dis*. 2012 Dec;25 (6):605-112012.

Ananda-Rajah M, Slavin MA, Thursky K.  
The case for antifungal stewardship.  
*Curr Opin Infect Dis*. 2012 Feb;25(1):107-15.

Chen SC-A, Slavin MA, Heath CH, Playford EG, Byth K, Marriott D, Kidd SE, et al; on behalf of the Australia and New Zealand Mycoses Interest Group (ANZMIG)-Cryptococcus Study. Clinical manifestations of *Cryptococcus gattii* infection: determinants of neurological sequelae and death  
*Clin Infect Dis* 2012; 55(6):789-798.

Gill S, Li J, Thomas J, Bressel M, Thursky K, Styles C, Tai KH, Duchesne GM, Foroudi F.  
Patient-reported complications from fiducial marker implantation for prostate image-guided radiotherapy.  
*Br J Radiol*. 2012 Jul;85(1015):1011-7.

Guy S, Thursky KA, Worth L, Tramontana A, Seymour JF, Lau E, Hicks R, Slavin MA.  
Use of FDG-PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients.  
*Eur J Nucl Med Mol Imaging*. 2012 May 15.

Haeusler GM, Slavin MA.  
Fluoroquinolone prophylaxis: worth the cost?  
*Leuk Lymphoma*. *Leuk Lymphoma*. 2013 Jan 2

Haeusler GM, Slavin MA.  
Complications of sepsis: the role of risk prediction rules, biomarkers and host genetics.  
*Expert Rev Anti Infect Ther*. 2012 Jul;10(7):733-5.

Heng SC, Slavin MA, Chen SCA, Heath CH, Nguyen Q, Billah B, Nation RL, Kong DCM.  
Hospital cost and outcome attributable to invasive scedosporiosis in hematology patients.  
*J Antimicrob Chemother* 2012;67(9):2274-82.

- Janson B, Thursky K.  
Dosing of antibiotics in obesity.  
Curr Opin Infect Dis. 2012 Dec;25(6):634-49.
- Koh KC, Slavin MA, Thursky KA, Lau E, Drummond E, Wong PS, Hicks R, Worth L.  
Impact of Fluorine-18 fluorodeoxyglucose positron emission tomography on diagnosis and antimicrobial utilization in high risk patients with febrile neutropenia.  
Leuk Lymphoma. 2012 Oct;53(10):1889-95.
- Leung VK, Harper SE, Slavin MA.  
Influenza vaccination uptake in an Australian hospital: time to make it mandatory for health care workers?  
Med J Aust. 2012 Nov 19;197(10):552.
- Livingston PM, Craike M, Slavin MA.  
Clinical and Economic Burden of Emergency Department Presentations Due to Neutropenia Following Outpatient Cancer Chemotherapy in Victoria Australia.  
Oncologist, 2012;17(7):998-1004.
- Neoh CF, Kong DCM, Slavin MA, Chen SCA.  
Pharmacological and host considerations surrounding dose selection and duration of therapy with echinocandins. Invited review.  
Current Fungal Infection Reports. Accepted.
- Slavin MA, Chakrabarti A.  
Opportunistic fungal infections in the Asia Pacific region.  
Med Mycol. 2012 Jan;50(1):18-25.
- Slavin MA, Chen SCA.  
Cryptococcosis, lymphoproliferative disorders and modern day chemotherapy regimens.  
Leuk Lymphoma. 2013 Mar;54(3):449-50.
- Slavin MA, McNeil Grist L.  
Invasive fungal infections: a continuing challenge.  
Current Fungal Infection Reports. Accepted September 2012
- Teh BW, Slavin MA.  
Staphylococcus aureus meningitis: Barriers to treatment.  
Leuk Lymphoma. 2012 Feb 23. [Epub ahead of print]
- Teh BW, Slavin MA, Szer J, Sasadeusz JJ.  
Hepatitis B serological changes following allogeneic bone marrow transplantation.  
Transplant Infectious Diseases, 2012 Jul 11.
- Teh BW, Worth LJ.  
Disseminated herpes simplex virus infection following epidermal growth factor tyrosine kinase inhibitor therapy for non-small-cell lung carcinoma.  
Intern Med J. 2012 Nov;42(11):1269-70.
- Worth LJ, McLaws ML. Is it possible to achieve a target of zero central line associated bloodstream infections?  
Curr Opin Infect Dis. 2012 Dec;25(6):650-7.

Worth LJ, Thursky KA, Slavin MA.  
Public disclosure of healthcare-associated infections Australia: quality improvement or parody?  
Med J Aust. 2012 Jul 5;197(1):29

## **Publications 2011**

Abbott IJ, Slavin MA, Turnidge JD, Thursky KA, Worth LJ.  
Stenotrophomonas maltophilia: emerging disease patterns and challenges for treatment of the immunocompromised host.  
Expert Rev Anti Infect Ther. 2011 Apr;9(4):471-88.

Ananda-Rajah MR, Cheng A, Morrissey CO, Spelman T, Dooley M, Neville AM, Slavin M.  
Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk haematology patients: an economic modeling approach.  
Antimicrob Agents Chemother. 2011 May;55(5):1953-60. Epub 2011 Feb 28.

Blombery P, Prince HM, Worth LJ, Main J, Yang M, Wood EM, Westerman DA.  
Prophylactic intravenous immunoglobulin during autologous haemopoietic stem cell transplantation for multiple myeloma is not associated with reduced infectious complications.  
Ann Hematol. 2011 Oct;90(10):1167-72.

Chakrabarti A and Slavin MA.  
Endemic Fungal infections in the Asia Pacific region.  
Med Mycol. 2011 May;49(4):337-44. Epub 2011 Jan 24.

Chen SCA, Blyth C, Sorrell TC, Slavin MA.  
Pulmonary Fungal Infections.  
Invited review, Semin Resp Crit Care Med. 2011; 32 (6): 703-16

Chen SCA, Slavin MA, Sorrell TC.  
Echinocandin antifungal drugs: a comparison.  
Drugs. 2011 Jan 1;71(1):11-4.

Doyle JS, Buising KL, Thursky KA, Worth LJ, Richards MJ.  
Epidemiology of infections acquired in intensive care units.  
Semin Respir Crit Care Med. 2011 Apr;32(2):115-38.

Lingaratnam S, Slavin MA, Mileskin L, Solomon B, Burbury K, Seymour JF, et al.  
An Australian survey of clinical practices in management of neutropenic fever in adult cancer patients 2009.  
Internal Medicine Journal 2011 Jan;41(1b):110-120

Lingaratnam S, Thursky KA, Slavin MA, Bennett CJ, Worth LJ.  
A Cost Analysis of Febrile Neutropenia Management in Australia: Ambulatory versus In-hospital Treatment Australian Health Review.  
Aust Health Rev. 2011 Nov;35(4):491-500.

Lingaratnam S, Thursky KA, Slavin MA, Kirsa SW, Worth LJ.  
The disease and economic burden of neutropenic fever in adult patients in Australian cancer treatment centres 2009: analysis of the Victorian Admitted Episodes Dataset.  
Internal Medicine Journal 2011 Jan;41(1b):121-9

Morrissey O, Sharon, Chen C-A, Sorrell TC, Bradstock KF, Szer J, Halliday CL et al.  
Design Issues in a Randomised Controlled Trial of Pre-emptive versus Empiric Antifungal  
Therapy for invasive aspergillosis in high-risk haematology patients (ASPID trial)  
Leuk Lymphoma. 2011 Feb;52(2):179-93

Neoh CF, Liew D, Slavin M, Marriott D, Chen S, Morrissey O, Stewart K, Kong D.  
Cost-effectiveness Analysis of Anidulafungin versus Fluconazole for the Treatment of  
Invasive Candidiasis(IC).  
J Antimicrob Chemother. 2011 Aug;66(8):1906-15.

Reid AB, Chen SC, Worth LJ.  
Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic  
tools.  
Curr Opin Infect Dis. 2011 Dec;24(6):534-44.

Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for  
haematological malignancies: are we there yet? Invited review.  
Br J Haematol. 2011 Jun;153(6):681-97.

Slavin MA.  
Challenges facing infectious diseases physicians today.  
Curr Opin Infect Dis. 2010 Dec;23(6):545.

Slavin, MA, Lingaratnam S, Mileskin, L  
Use of antibacterial prophylaxis for patients with neutropenia.  
Internal Medicine Journal 2011 Jan;41(1b):102-9

Tam C, O'Reilly M, Andresen D, Lingaratnam S, Kelly A, Burbury K, Turnidge J et al.  
Use of empiric antimicrobial therapy in neutropenic fever.  
Internal Medicine Journal 2011 Jan;41(1b):90-101.

Wong PS, Lau EWF, Worth LJ, Thursky KA, Drummond E, Slavin MA, Hicks R.  
Clinically important detection of infection as an 'incidental' finding during cancer staging  
using FDG-PET/CT.  
Intern Med J. 2011 Feb 10.

Worth LJ, Lingaratnam S, Taylor A, Hayward AM, Morrissey S, Cooney J, Bastick PA et al.  
Australian Consensus Guidelines 2011 Steering Committee.  
Intern Med J. 2011 Jan;41(1b):82-9.